Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study

Background and objectives: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g...

Full description

Saved in:
Bibliographic Details
Main Authors: Fervenza, Fernando C., Abraham, Roshini S., Erickson, Stephen B., Irazabal, Maria Valentina, Eirin, Alfonso, Specks, Ulrich, Nachman, Patrick H., Bergstralh, Eric J., Leung, Nelson, Cosio, Fernando G., Hogan, Marie C., Dillon, John J., Hickson, LaTonya J., Li, Xujian, Cattran, Daniel C.
Format: Artigo
Language:Inglês
Published: American Society of Nephrology 2010
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994079/
https://ncbi.nlm.nih.gov/pubmed/20705965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05080610
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items